Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Risedronate · 1 trial · 1 indication
change in spine bone density at 18 months measured by DXA 18 and 24 months
| Arm | Type | Description |
|---|---|---|
| Active Risedronate Placebo Teriparatide | ACTIVE_COMPARATOR | Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months |
| Active Risedronate Active Teriparatide | ACTIVE_COMPARATOR | Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months |
| Placebo Risedronate Active Teriparatide | ACTIVE_COMPARATOR | Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months |
| Name | Type | Description |
|---|---|---|
| Risedronate | DRUG | weekly risedronate |
| Teriparatide | DRUG | daily teriparatide |
| Placebo Teriparatide | DRUG | daily placebo of teriparatide |
| placebo Risedronate | DRUG | weekly placebo of Risedronic Acid |
Inclusion Criteria: 1. Males, ages 30-85 with osteoporosis. 2. Osteoporosis can be due to hypogonadism, past steroid use, or idiopathic. 3. Patients with hypogonadism can be included if their replacement dosage of testosterone has been stable for at least 18 months. 4. Bone mineral density must be ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |